A Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of RX-3341 Compared with Cefazolin for the Prevention of Surgical Site Infections Following Coronary Artery Bypass Graft Surgery

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/081/31/09

Funding

  • RibX Pharmaceuticals Inc: $2,472.00